IDEAYA Biosciences Forms Clinical Partnership with Roche for Pancreatic Cancer
IDYA sits 38% above its 52-week low of $19.83.
Summary
IDEAYA Biosciences announced a clinical collaboration with Roche to evaluate a combination therapy for MTAP-deleted RAS-mutant pancreatic cancer. The companies will jointly govern the trial and initiate Phase 1 combination cohorts in both pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC). This follows an 8-K filed earlier today and builds on recent positive developments, including a prior collaboration with AstraZeneca and strong Phase 2/3 data for darovasertib. Partnering with a major pharma like Roche validates IDEAYA's pipeline and expands its clinical development efforts into challenging oncology indications.
At the time of this announcement, IDYA was trading at $27.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $19.83 to $39.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.